据印度代购了解，目前国内很多肺癌患者对凯美纳(埃克替尼)和易瑞沙等药都非常熟悉，但也有一些刚确诊的患者对此药并不十分熟悉，因此会有凯美纳(埃克替尼)耐药、易瑞沙耐药等问题。其中令小编最感兴趣的问题就是凯美纳(埃克替尼)耐药后是否可以服用易瑞沙?就此问题我们一起来了解一下吧。

 According to Daigu India, many lung cancer patients in China are very familiar with kemena (ectinib) and irressa and other drugs, but there are also some newly diagnosed patients are not very familiar with this drug, so there will be kemena (ectinib) drug resistance, irressa and other problems. One of the most interesting questions for xiaobian is whether iressa can be taken after drug resistance to Camena (ectinib)? Let's take a look at this question.

印度代购提示您，本品凯美纳(埃克替尼)：

据印度代购了解，凯美纳(埃克替尼)在治疗肿瘤上是一种特异性的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)。主要适用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌，既往化疗主要是指以铂类为基础的联合化疗。

印度代购提示您，本品易瑞沙：

据印度代购了解，易瑞沙适用于治疗既往接受过化学治疗的局部晚期或转移性非小细胞肺癌(NSCLC)。既往化学治疗主要是指铂剂和多西紫杉醇治疗。对于化学治疗失败的局部晚期或转移性非小细胞肺癌患者的疗效，是基于客观反应率指标而确立的，尚无对照性的研究显示改善疾病相关症状和延长生存期方面的临床受益

据印度代购了解，以上这两种药都可用于非小细胞肺癌的治疗。只是易瑞沙为进口药，凯美纳(埃克替尼)为国产药，疗效大尽相同。

据印度代购了解，拒不完全统计，凯美纳(埃克替尼)耐药后吃易瑞沙的患者，能续活两年以上，但是能续活五年以上的凤毛麟角。当然生存期的长短还是需要根据患者个体情况来判断的!

According to Daigou India, although complete statistics are not available, patients who take iressa after drug resistance to kemena (ectinib) can continue to live for more than two years, but few can continue to live for more than five years. Of course, the length of the survival period still needs to be judged according to the individual situation of patients!